288 results about "Pharmacologic therapy" patented technology

The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention discloses a preparation method and application of a granzyme B response near-infrared two-region ratiometric fluorescent probe (DCGA). The DCGA combines the NIR-II dual-emission fluorescence characteristic of rare earth ions with a ratio-type signal response mode, the sensitivity and signal stability of in-vivo fluorescence imaging are greatly improved, ultralow or enhanced F1060nm fluorescence signals are respectively shown before and after interaction with granzyme B (GzmB), F1525nm fluorescence signals are almost kept unchanged, and the DCGA can be used for detecting the in-vivo fluorescence imaging of the granzyme B (GzmB). Therefore, the self-calibration ratio fluorescence imaging GzmB activity change is realized. The DCGA is applied to tumor treatment of immunotherapy drugs, and responders and non-responders of immunotherapy can be distinguished in a non-invasive early stage through ratio fluorescence signals of the DCGA. Therefore, the fluorescent probe can be used as an effective GzmB active NIR-II ratio fluorescence imaging tool, and is expected to provide powerful support for immunotherapy research, precision medicine and personalized diagnosis and treatment.

The invention relates to an application of alvitinib in preparation of an NLRP3 inflammasome inhibitor. The alvetinib is used for preparing a medicament for treating infectious shock, a medicament for treating acute liver injury and a medicament for treating peritonitis. A new choice is provided for prevention or treatment of NLRP3 inflammasome related diseases, the problem of treatment of EGFR mutation lung cancer patients combined with NLRP3 inflammasome related diseases (infectious shock / acute liver injury / acute peritonitis) is solved, tumor progression and inflammatory response are inhibited at the same time through the Aviitinib (third-generation EGFR-TKI), and the NLRP3 inflammasome related diseases are treated through the Aviitinib (third-generation EGFR-TKI). It is suggested that the medicine is preferentially selected by the patients, and the medicine with higher treatment potential is provided for treatment of infectious shock medicines, acute liver injury medicines and acute peritonitis.

The inventive subject matter is directed to inflatable pillows that are useful in the context of non-pharmaceutical therapies. Pillows of the inventive subject matter comprise a hexagonal top surface, a hexagonal bottom surface, and one or more pockets that allow users to place warming / cooling pads beneath the top surface of the pillow. In some embodiments, up to three pockets can be included, where each pocket is accessible along an edge of the top surface. When divided into third, each pocket can be accessible along an edge of the hexagonal outer edge of the top surface such that a user's neck can rest along that edge to improve contact with a warming / cooling pad. Embodiments include an air hub to facilitate inflation and deflation, and a stiff pillow base can be included as well.

The invention relates to the technical field of medical information, in particular to an endocrine patient long-term medication tracking management method and system, and the method comprises the following steps: extracting multiple pieces of key information in a prescription based on the electronic prescription information of a patient, recognizing the taking time and dosage information of multiple medicines, and sending medication reminding information to the patient, by monitoring the opening and closing state of the medicine box, the medicine taking time and quantity are recorded, and reminding and medicine taking monitoring information is generated. According to the method, the opening and closing state of the medicine box is monitored in real time, the taking time and quantity of medicine are recorded, the transparency of medicine treatment and the compliance of a patient are improved, physiological parameters of the patient are collected regularly, time sequence analysis and doctor feedback are matched, the change trend and periodic fluctuation of the illness state of the patient are accurately recognized, and the patient compliance is improved. By analyzing drug use logs of patients and doctors, effects of various drugs are identified, side effects are detected, drug doses and types are helped to be adjusted in time, the risk of adverse drug reactions is effectively reduced, and the treatment effect is improved.

Various methods and systems for efficiently providing pharmacogenetic guidelines is disclosed. A drug prescription and a patient genotype can be analyzed to provide a drug therapy recommendation. The analysis can include comparing the patient genotype and the drug name to a drug profile database, a molecular biomarker database, hospital drug reaction records and omics databases, and calculating the patient response to the drug.

The invention discloses a combined treatment medicine for acute myelogenous leukemia. The combined treatment medicine is prepared from vinaclaria, azacitidine and aclarithromycin. The medicine is applied to preparation of an acute myelogenous leukemia cell proliferation inhibitor; the medicine is applied to preparation of an acute myelogenous leukemia cell apoptosis inducer. The three medicines are combined to achieve a synergistic effect: the three medicines have a synergistic anti-tumor effect instead of a simple superposition effect, and a new combined medication mechanism is a result obtained through laboratory research and an initial effect of clinical application. The subsequent consolidation treatment scheme may also be used for part of initially treated patients with acute myelogenous leukemia, which are not suitable for enhanced chemotherapy or intense intense treatment by using targeted drugs, and relapse / refractory patients with acute myelogenous leukemia, and a better treatment scheme can also bring new hope and dawn to more patients.

Compositions, systems, and methods for and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve selection of a subject that is naïve for at least one standard-of-care chemotherapeutic drug (such as, but not limited to, a fibrotic-inducing chemotherapeutic agent), followed by application to the selected subject of an alternating electric field. The method may further include concurrent administration of at least one chemotherapeutic agent to the subject.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The invention relates to the technical field of medicines, in particular to application of KLB protein in preparation of a medicine for treating schistosome infection. The invention verifies the treatment effect of the KLB protein on hepatic tissue EMT and fibrosis caused by schistosoma japonicum infection, and proves that the KLB can be used as a medicine for treating schistosoma japonicum hepatic fibrosis.

The invention provides application of a CHD1L detection reagent in preparation of a drug-resistant breast cancer screening kit, and belongs to the field of biological medicine. Researches find that when the CHD1L gene expression level in cancer tissues of a breast cancer patient is high, the breast cancer patient is prone to drug resistance to paclitaxel drugs, and the treatment effect of the paclitaxel drugs is poor. The reagent for detecting the CHD1L gene expression level is used for preparing the drug-resistant breast cancer screening kit, can be used for auxiliary diagnosis of clinical breast cancer types, provides an effective basis for related treatment measures or decisions of patients, and has a good clinical application prospect.

Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.

The invention discloses application of selazinomethyl ether and a pharmaceutical composition thereof in preparation of a medicine for preventing or treating brain injury. The invention provides the application of selazine methyl ether in preparing the medicine for preventing or treating the brain injury for the first time, and selazine methyl ether has a remarkable effect in preventing or treating the brain injury, especially cerebral arterial thrombosis and the brain injury caused by hemorrhagic transformation of the cerebral arterial thrombosis. And cerebral injury caused by cerebral arterial thrombosis and hemorrhagic transformation can be obviously relieved. According to the application disclosed by the invention, the sefoazinomethyl ether has the effects of remarkably reducing the cerebral infarction area and behavioral scoring under the condition of middle cerebral artery occlusion; the selobezine methyl ether has the effects of remarkably reducing the hemorrhage area, hemorrhage score and behavioral score under acute high glucose and middle cerebral artery occlusion; the pharmaceutical composition containing selazine methyl ether can become a novel drug for preventing or treating brain injury, and can be used for treating various cerebrovascular diseases including cerebral arterial thrombosis and hemorrhagic transformation of cerebral arterial thrombosis.

A method for treating inflammatory bowel disease using prolyl hydroxylase domain-containing protein (PHD) inhibitors and additional agents is described herein.

The invention provides an application of a human C1orf186 gene or a human C1orf186 protein in preparation of a targeted therapeutic drug for ovarian cancer, and relates to the technical field of biomedical engineering. The invention relates to an application of a human C1orf186 gene or a human C1orf186 protein in preparation of an ovarian cancer targeted therapy drug. Experiments prove that C1orf186 is an ovarian cancer cell surface specific membrane protein molecule, a C1orf186 positive cell population has tumor stem cell characteristics, and prepared human C1orf186 lentivirus packaging plasmids and other targeted therapeutic drugs have an obvious inhibition effect on the growth of ovarian cancer. Therefore, the invention provides a specific target C1orf186 for molecular therapy of the ovarian cancer, also provides several targeted drug types, and more importantly provides a thought for treating the ovarian cancer by using the anti-C1orf186 targeted drug, thereby laying a foundation for deeply researching the function of the C1orf186. Meanwhile, the invention provides reliable theoretical basis and experimental data for clinical treatment of ovarian cancer, and has important significance and wide prospects.

The invention provides an abnormal glycolipid metabolism risk dynamic assessment system based on SNP and gene analysis and application of the system in neuropsychiatric drug therapy, and belongs to the technical field of biological medicine. The system disclosed by the invention contains the primer probe group for detecting the metabolic influence of the antipsychotic drug, so that specific amplification detection of a specific SNP site can be realized, clinical guidance is targeted, and abnormal glucose and lipid metabolism and significant change of body weight are avoided. According to the method, glucose and lipid metabolism and effect target gene detection products are adopted for detection, a detection result is evaluated and interpreted through a glucose and lipid metabolism abnormal risk dynamic evaluation algorithm, retrospective investigation and actual case observation are combined, the detection result is good in sensitivity, high in accuracy and high in practicability, sampling is convenient, the evaluation algorithm is professional and reasonable, and the method is suitable for popularization and application. Results are easy to understand and easy to popularize and use.

A technique is provided for identifying correct or sufficient doses in a patient being treated with a drug for a neurological deviation condition. A method may include performing a plurality of fright response tests on a user, each test utilizing a device having a camera, a display, and optionally a speaker, and each test occurring at a different time after the user has been administered a medicament. The method may include receiving a plurality of images of at least one eye of the user from a camera during each test, and then calculating a magnitude of eyelid closure based on each image. The method may include determining a value of a correlation between a predetermined plasma concentration of the drug and the determined amplitude, and then determining whether a correct or sufficient dose has been reached based on the value of the correlation.

The invention discloses an inflammatory pulmonary epithelium injury treatment evaluation method based on alveolar organs, and relates to the technical field of medical biology. The invention mainly aims at alveolar epithelium injury and repair in inflammatory lung injury, and establishes an organ-like model for simulating alveolar epithelium injury. By using the model, the efficacy of related drugs on alveolar epithelium injury repair can be detected in a targeted manner, and an efficient drug screening and evaluation platform and method are provided for pulmonary epithelium repair in inflammatory lung injury. According to the technical scheme, the method comprises the steps that mouse alveolar epithelial stem cells are separated through magnetic bead sorting, an alveolar organoid inflammatory lung injury model is established through LPS exposure, alveolar organoid is treated through drugs, the organoid generation number, the organoid formation rate, the epithelial cell proliferation rate and the AT2-AT1 differentiation efficiency are detected, and the drug treatment effect is evaluated.

The invention discloses an STING agonist polypeptide conjugate as well as a composition and application thereof, and belongs to the field of medicinal chemistry, an STING agonist and a straight-chain peptide or a cyclic peptide are directly connected or connected through a linking group, the formed conjugate can target a tumor microenvironment, and the STING agonist is controllably released in specific time and space, so that the tumor microenvironment is inhibited, and the tumor microenvironment is inhibited. Therefore, the drug enrichment amount of the tumor site is increased, the drug treatment efficiency and bioavailability are improved, the toxic and side effects are reduced, and the purposes of effect enhancement and toxicity reduction are achieved. According to the STING agonist polypeptide conjugate, the targeting property of STING agonist drugs on tumor tissues is improved, the toxic and side effects on normal tissues are reduced, the STING agonist polypeptide conjugate is a brand-new immune agonist type coupling drug, and a new scheme is provided for tumor immunotherapy research.

In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and / or an anti-IL-12 / 23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and / or and a sphingosine-1-phosphate receptor agonist agent.

Provided are therapies and regimens for treating chronic diseases, disorders and conditions having multiple intervention targets and / or treatment targets. The therapies include administration of a combination regimen and administration of an alternating combination regimen. The regimen comprises a combination of pharmaceutical and / or non-pharmaceutical treatments.

The invention relates to the technical field of physiological monitoring, in particular to a hepatocellular carcinoma treatment effect analysis system and method based on metabolism comprehensive analysis, and the method comprises the steps: obtaining the evolution condition of hepatocellular carcinoma, the composition condition of drugs and the composition condition of metabolites; drug absorption and transformation analysis is carried out based on the composition condition of the drug and the marking condition of the composition condition of the metabolite, future drug transformation component prediction is carried out based on the drug absorption and transformation analysis result and the evolution condition of the corresponding hepatocellular carcinoma, and drug treatment effect early warning is carried out based on the future drug transformation component prediction. The first-pass effect is corrected through mass spectrum imaging and enzyme activity, the inhibition effect of the tumor microenvironment on drug transformation is quantified, prediction is dynamically adjusted through the future tumor anomaly score ratio, and the accuracy of the time of drug replacement is improved.

The present invention discloses a lipid prodrug nanoassembly based on dynamic covalent chemistry, and its preparation method and application, which belong to the fields of dynamic binding chemistry and nanotechnology. The present invention designs a dynamic covalent chemical lipid nano drug delivery system, which is mainly obtained by self-assembly of lipid molecules with a hydrophilic head, a hydrophobic tail and a dynamic covalent side chain. The molecule has an o-diphenol side chain group and can be combined with anti-cancer, antibacterial and antifungal drugs, and has good anti-tumor and antibacterial effects. The present invention constructs a lipid drug delivery platform through dynamic covalent chemistry for the first time, which has the advantages of responsiveness, fixed point, on-demand release, etc. in terms of function. It combines a variety of drugs such as anti-cancer, antibacterial and antifungal drugs with lipid molecules through dynamic covalent chemistry to improve the therapeutic effect of drugs.

The invention provides a traditional Chinese medicine composition for treating Alzheimer's disease. Relates to the technical field of traditional Chinese medicine preparations, the weight part ratio of rhizoma polygonati to radix astragali is 1: (1-1.2), a progressive increase type structure is adopted among rhizoma polygonati, radix astragali and poria cocos, and the progressive increase type structure meets the condition that radix astragali is larger than or equal to poria cocos and is larger than or equal to rhizoma polygonati; the sum of the parts by weight of the basic support components accounts for 40-55% of the total parts by weight of the traditional Chinese medicine composition. According to the traditional Chinese medicine composition for treating the Alzheimer's disease, the basic support component, the collateral dredging and regulating component and the active intervention component are reasonably distributed through a definite fixed matching structure, and it is ensured that all the components cooperate with one another and act more stably. By setting an incremental structure and a bidirectional locking proportional structure between the medicinal materials, the composition fluctuation is reduced, so that the composition of each batch has higher consistency, and the stability of the treatment effect of the medicine is enhanced.

The application provides a method for constructing a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model and application thereof. The non-human animal model of spontaneous esophageal precancerous lesion or esophageal cancer is obtained by deleting the expression of Trp53 and Cdkn2a in the non-human animal. The non-human animal model prepared by the application can be used as an ideal animal model for screening drug candidates, evaluating the therapeutic effect of drugs, evaluating the toxicological effect of drugs and researching the pathogenesis of esophageal precancerous lesion or esophageal cancer.

The present invention provides a fusion protein composed of an anti-human CTGF antibody and the extracellular domain of the human type II TGF-β receptor, linked via a linker. This fusion protein can bind both CTGF and TGF-β. This fusion protein can be purified in a single step to obtain a 100% pure target protein. Experiments have shown that even a low dose of 1 mg / kg can significantly reduce the degree of pulmonary fibrosis in experimental animals.

The invention discloses a preparation method and application of tanshinone IIA and cryptotanshinone amide derivatives. The tanshinone IIA and cryptotanshinone amide derivatives are compounds shown in a general formula (I) or stereoisomers, racemes, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs of the compounds. The tanshinone IIA and cryptotanshinone amide derivative can be used for preparing anti-inflammatory drugs, antibacterial drugs, tumor drugs, drugs for treating cardiovascular and cerebrovascular diseases, drugs for treating burns and scalds and drugs for treating infectious diseases.

The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and / or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.